US-UK Pharma Deal: Tariff Relief for Britain, Price Hikes for NHS

A landmark pharmaceutical partnership between the United States and the United Kingdom has officially come into effect, eliminating tariffs on U.S. Drug exports to the UK. However, this tariff reprieve comes at a cost: the UK’s National Health Service (NHS) will see a 25% increase in the net price it pays for novel treatments.

Deal Details and Economic Impact

The agreement, initially outlined in December 2025, secures 0% tariffs on U.S. Pharmaceutical exports to the UK, making it the first nation globally to achieve this status Fierce Pharma. This move is intended to revitalize investment in the UK’s pharmaceutical industry, which contributed £28.5 billion to the UK economy in 2025 and employs over 50,000 people Fierce Pharma. The industry as well exported nearly £21 billion in pharmaceutical products worldwide last year Fierce Pharma.

Impact on the National Health Service (NHS)

The 25% price increase will be implemented through a revised cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) when evaluating new medicines Fierce Pharma. Historically, NICE considered drugs cost-effective if they offered benefits within a range of £20,000 to £30,000 per quality-adjusted life year (QALY) gained Fierce Pharma. As of March 31, 2026, this range has been adjusted to £25,000 to £35,000 per QALY Fierce Pharma.

Broader US Tariff Policy and Exceptions

Alongside the UK agreement, President Donald J. Trump imposed a 100% tariff on patented pharmaceutical products and ingredients to strengthen U.S. National security and supply chains The White House. However, exceptions exist. Pharmaceutical products originating from the European Union, Japan, Korea, and Switzerland/Liechtenstein are subject to a 15% tariff The White House.

Companies that enter into Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services (HHS) and onshoring agreements with the Department of Commerce will be exempt from tariffs through January 20, 2029 The White House. Those who only agree to onshoring will face a 20% tariff The White House. Generic pharmaceuticals and certain specialty drugs are currently exempt from these tariffs, though this may be reassessed in one year The White House.

Context and Objectives

The deal builds upon the U.S.-UK Economic Prosperity Deal established in May 2025, aiming to foster shared economic prosperity Gov.uk. Both nations recognize the importance of fair pricing for pharmaceutical innovation and strengthening pharmaceutical supply chain resilience Gov.uk.